Curriculum Vitae Solange PETERS, MD-PhD · Permanent advisory board member for Framingham on lung...

Curriculum Vitae – Solange PETERS, MD-PhD

Charles-Secrétan 17 | 1005 Lausanne | Switzerland | [email protected] | +41 795560192 1

1. Personal Data

Name: Solange PETERS, MD-PhD Hospital address: Centre Hospitalier Universitaire Vaudois (CHUV) Oncology Department, Lausanne, Switzerland Date / Place of birth: December 20th 1972, Lausanne, Switzerland Family: 2 children, Eliott 2004 and Lucie 2007 Languages: French, English, Italian, German

2. Education

2002 Degree of MD-PhD, University of Lausanne: HIV drug resistance 1998 Federal Diploma of Medicine (MD), University of Lausanne 1997 Molecular virology certificate 1997 Faculty of Science, University of Lausanne: Molecular biology certificate 1995 – 1996 University of Bari, IT 1992 – 1998 Medical School, University of Lausanne 1991 High School (Gymnasium), Lausanne

3. Postgraduate Qualifications

Current Position: CHUV Medical Oncology Service Chief – Associate Professor – chair of Thoracic Oncology, Chief Resident in charge of thoracic malignancies, Oncology Department, University Hospital of Lausanne (CHUV), Médecin Cheffe

2009 – 2015 Chief Resident in charge of thoracic malignancies, Oncology Department, University Hospital of Lausanne (CHUV)

2013 Academic grade: Privat Docent and Maitre d’Enseignement et Recherche (PD-MER1) 2009 Nomination as Senior physician ("Médecin Associé") at the University Hospital of

Lausanne 2012 GCP training: Clinical Investigators II: Advanced GCP and clinical research training

course, CTU Bern & SAKK Bern, Feb 13 and 20, 2012 2006 SSMO (Swiss Society of Medical Oncology), oral exam 2006 ESMO (European Society for Medical Oncology) exam in oncology (renewed in 2012) 2006/2010/2012 Training and certification in "Good Clinical Practices for investigators and study

coordinators" (Swissmedic level 1-3) 2006 Training in communication "Mieux communiquer" (Ligue suisse contre le cancer) 2005 Multidisciplinary Oncology Center, University Hospital of Lausanne, Fellowship 2002 – 2005 Internal Medicine Department, University Hospital of Lausanne, Residency in Internal

Medicine (Oct 2002–Oct 2003 Multidisciplinary Oncology Centre)

mailto:[email protected]



4. Teaching activities

2008 – In charge of thoracic malignancy and part of general oncology education/teaching at the Faculty of Biology and Medicine of Lausanne, Switzerland

2008 – Multidisciplinary regional teaching in general/thoracic oncology (E.g. Espace Compétences (nurses), Swiss & German Societies of pathology, Groupement des Oncologues Genevois)

2008 – Teacher in educational programs in Switzerland (SAKK, SAMO, Forome), for national oncology societies (Netherland, Greece, France, Italy, Spain, Denmark, Sweden, Japan, China, Brazil,…) and internationally on behalf of ASCO, BTOG, CECOG, ECCO, ESMO, ESO, ESTRO, ESTS, and IASLC.

5. Selected memberships and officer in societies

ESMO (European Society for Medical Oncology): 2018 - ESMO Congress 2018 Scientific Chair 2016 - ELCC 2016 Scientific Chair 2014 – - Women for Oncology Task Force / Committee Chair 2014 – - Executive Board Member, Press & Media Affairs Committee Chair 2013 – 2014 - Elected National Representative 2012 – 2014 - E-Learning and CME Working Group (ECWG) Member 2012 – - Faculty Member IASLC (International Association for the Study of Lung Cancer): 2014 – - Publication Committee Member 2013 – 2017 - Elected Board of Directors Member ETOP (European Thoracic Oncology Platform): 2016 – - Foundation Council Member 2012 – - Scientific Coordinator 2011 – - Chair of Information & Communication Committee FOROME (Association Romande pour la formation continue en oncologie médicale): 2012 – - President SAKK (Swiss Group for Clinical Cancer Research): 2011 – 2017 - Vice President 2003 – - Lung cancer group member SAMO (Swiss Academy for Multidisciplinary Oncology): 2015 – - Vice President 2011 – - Board member SSOM (Swiss Society of Medical Oncology): 2013 – 2014 - Board member, in charge of education program 2005 – - Member FMH (Association of Swiss Physicians): 2013 – 2014 - In charge of subspecialty title recognition/attribution at national level 2002 – - Member 2013 – 2015 Swiss Institute for Postgraduate and Continuing Medical Education: Board member 2007 – AACR (American Association for Cancer Research): Member 2002 – ASMAC/VSAO (Association of Swiss Interns and Residents): Member




6. Chairman activities

2018 ESMO 2018 Congress: Scientific Chair 2016 ELCC 2016 (European Lung Cancer Conference): Chair 2014 ESMO 2014 Congress: Lung Cancer track chair (advanced disease) 2013 Swiss Post-ASCO Co-Chair (speaker at Brazilian and Chinese Societies for Medical Oncology

national post-ASCOs) 2010 – SAMO Lung Co-Chair (annual meetings)

7. Research grants

Peters as PI/Chair 2015 – 2017 Swiss Cancer Research KFS-3458-08-2014: Role of RANK signaling in non-small cell lung cancer 2014 – SPECTALung (Screening patients with thoracic tumors for efficient clinical trial access),

EORTC/ETOP sponsored 2014 – NICOLAS (Nivolumab Consolidation after standard first-line chemotherapy and radiotherapy

in locally advanced stage IIIA/B NSCLC), ETOP sponsored 2014 – NICHE: Afatinib in NSCLC with HER2 mutation, ETOP sponsored 2014 – SPLENDOUR (Survival improvement in lung cancer induced by denosumab therapy), ETOP

sponsored, EORTC coordinating group 2014 – Gateway Award (with Rising Tide Foundation) CATATeM: A Phase IB/II Study of Combination

Treatment with Carboplatin/Paclitaxel and the Copper Chelator, Tetrathiomolybdate in Patients with Advanced Solid Tumors

2013 – STIMULI (Small cell lung cancer trial with ipilimumab in limited disease), ETOP sponsored 2013 Roche unrestricted grants: lung cancer risks factors, focusing on HIV 2012 – EMPHASIS (Erlotinib MALDI TOF phase III signature in squamous cell non-small cell lung

cancer), ETOP sponsored 2012 – LUNGSCAPE, a project of ETOP, ETOP sponsored 2012 Award/Research grant Dr Arnold U. und Susanne Huggenberger-Bischoff Stiftung zur

Krebsforschung (Krebsstiftung): ALK biology/RT-PCR 2009 – 2015 SAKK 16/08 trial: Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in

non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial

Peters as co-PI 2015 – 2017 Swiss National Science Foundation 320030_160106: Photo-Induction as a mean to improve

cisplatin delivery to pleural malignancies: a clinical phase I and targeted phase II expansion cohort trial

2012 Oncosuisse grant KFS-3057-08-2012: Notch signaling in lung squamous cell carcinoma 2011 – 2014 Swiss national Science Foundation 320030-135197: Low-dose photodynamic therapy

selectively enhances liposomal doxorubicin uptake to superficially spreading pleural tumors

8. Scholarships and awards

2014 Prix de la Faculté de Biologie et Médecine de Lausanne pour excellence en recherche clinique 2008 Grant for ECCO-AACR-EORTC-ESMO Workshop "Methods in Clinical Cancer Research" Flims,

Switzerland 2006 Best European Exam Result Award, ESMO (European Society for Medical Oncology) exam 1999 – 2002 Swiss National Science Foundation MD-PhD grant: HIV drug resistance




9. Editorial functions

2016 – Editor in chief Resource Center “Milestones in Non-Small-Cell Lung Cancer (NSCLC)” by Elsevier and the Journal of Thoracic Oncology

2012 – Deputy Editor: Journal of Thoracic Oncology Leading selection and transition to a new publisher in 2015/16

2013 – 2017 ESMO guidelines editor for thoracic malignancies 2012 – 2013 ESMO guidelines co-editor for thoracic malignancies 2013 – 2016 Editor in Chief: Cancer Treatment Communications 2013 – 2016 Co-editor in Chief: Journal of Oncopathology 2013 – Co-Editor ESMO Thoracic Tumours essentials 2014 – Editorial board member: European Medical Journal - Oncology 2013 – Editorial board member: Targeted Oncology 2013 – Associate Editor: Frontiers in Pharmacology and Anti-Cancer drug 2011 – 2012 Associate Editor: Lung Cancer

10. Referee for scientific journals / grant reviews

Review editor: Frontiers in Thoracic Oncology

Grant Reviewer for Swiss National Science Foundation (SNF)

Grant Reviewer for the Swiss Cancer League Grants

Grant Reviewer fond de dotation “Recherche en Santé Respiratoire” (France)

Grant Reviewer and Scientific committee “Fondazione San Salvatore”

Advisor National and Kapositrian University of Athens

Permanent advisory board member for Framingham on lung cancer journal

Reviewer in: Lancet Oncology, Journal of Clinical Oncology, Thorax, Chest, European Respiratory Journal, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer, Cancer, Annals of Thoracic Surgery, Lung Cancer, Oncology, Radiation Oncology

11. Political commitments

Head of main Swiss political group of the agglomeration for 8 years (2003–2011)

Elected city parliament 4 times, active > 15 years since 1998

Elected to Swiss National Parliament (2007)

Member of « Le Passage » Foundation Council for 4 years (vulnerable populations) 2011–2015

Elected President of « Centre de liaison des Associations Féminines Vaudoises (CLAFV) » for 4 years (2005–2009)

External advisor for Swiss cancer plan 2018

12. Hobbies and public activities

Competitive swimmer, currently very active in sport: running/swimming/ski

MBA in health economics (ongoing)




Publication List Peer-Reviewed Publications

120. Haanen JBAG, Carbonnel N, Robert C, Kerr K, Peters S, James Larkin J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Submitted

119. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azabuja E, Henriksson R, Boulanger T, Keilholz U, Peters S, Watts C, Wick W, Wesseling P, Ruda R, Preusser M. EANO ESMO Recommendations for the Diagnosis and Treatment of Leptomeningeal Metastasis from Solid Tumors. Submitted

118. Finn S, Letovanec I, Zygoura P,Smyth P, Soltermann A, Bubendorf5 L, Speel E.J, Marchetti A, Nonaka D, Monkhorst K, Hager1 H, Martorell M, Sejda A, Cheney A, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans A.-M, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger J, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S. Evaluation of NGS and RT-PCR methods for ALK assessment in European NSCLC patients: Results from the ETOP Lungscape Project. Submitted

117. Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E,

Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger T, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters P, Stahel RA, for the Lungscape Consortium. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Submitted.

116. Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans A-MC, Priest L, Bass P, Camps C, Weder W, Polydoropoulou V, Geiger T, Kammler K, Molina MA, Sumiyoshi T, Shames DS, Stahel R, Peters S, ETOP Lungscape Consortium. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. Submitted

115. Peters S, Kerr K, Stahel R. PD-1 blockade in advanced NSCLC: a focus on pembrolizumab. Submitted

114. Peters S*, Camidge R*, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, S-HI Ou, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T. Alectinib versus Crizotinib in Untreated ALK+ Non-Small-Cell Lung Cancer. 2017; NEJM, in press

113 Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel M, Ciuleanu TE, Badin F, Ready N, Hiltermann JN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Abreu DR, Borghaei H, Blumenschein GR, Villaruz L, Havel L, Krejci J, Corral Jaime J, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA. First-line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. 2017, NEJM, in Press




112. De Rossi N, Dattner N, Cavassini M, Peters S, Hugli O, Darling KEA.Patient and doctor perspectives of HIV screening in the emergency department: a prospective cross-sectional study. 2017, Aids Care. In Press

111. Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Keong Toh C, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares JL, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab as First-line or Subsequent Therapy for Patients with PD-L1–Selected Advanced Non-Small Cell Lung Cancer (BIRCH). J Clin Oncol, 2017. In Press

110. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palermo R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina M-A, Stahel RA, for the BELIEF collaborative group. A phase II trial of erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Lancet Respir Med. 2017 ; 5(5):435-444

109. Nguyen-Ngoc T, Reck M, Tan Shao Weng D, Peters S. Immunotherapy and targeted therapies in the treatment of NSCLC. European Oncology and Haematology. In press

108. Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol. 2016; pii: S1556-0864(16)33607-3

107. Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients with Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer. 2016; pii: S1525-7304(16)30361-8

106. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017;12(2):194-207.




105. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard J-Y, McGregor K, Ciardiello F. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open Jan 2017, 1(6), e000142

104. Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open Jan 2017, 1(6), e000118

103. Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, e Azambuja, E Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard J-Y, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). ESMO Open Jan 2017, 1(6), e000107.

102. Serena A, Castellani P, Fucina N, Griesser AC, Jeanmonod J, Peters S, Eicher M. The role of advanced nursing in lung cancer: A framework based development. Eur J Oncol Nurs. 2015 Dec;19(6):740-6

101. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AMM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open 2016;1:e000142.

100. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crino L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2016. pii: S1556-0864(16)31142-X.

99. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S; ESMO Guidelines Committee. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v1-v27

98. Früh M, Ris HB, Xyrafas A, Peters S, Mirimanoff RO, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. Ann Oncol. 2016;27(10):1971-3

97. Merz L, Zimmermann S, Peters S, Cavassini M, Darling KE. Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. Oncologist. 2016;21(10):1176-1182

96. Pietanza MC, Zimmerman S, Peters S, Curran WJ Jr. Seeking New Approaches to Patients With Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2016;35:e477-82


http://www.ncbi.nlm.nih.gov/pubmed/27249756

http://www.ncbi.nlm.nih.gov/pubmed/27249756



95. Abdelnour-Berchtold E, Perentes JY, Ris HB, Beigelman C, Lovis A, Peters S, Krueger T, Gonzalez M. Survival and Local Recurrence After Video-Assisted Thoracoscopic Lung Metastasectomy. World J Surg. 2016;40(2):373-9

94. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139-62

93. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA,. Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016; 11(5):613-38

92. Péguret N, Ozsahin M, Zeverino M, Belmondo B, Durham AD, Lovis A, Simons J, Long O, Duclos F, Prior J, Denys A, Beigelman C, Sozzi WJ, Grant K, Gautier-Dechaud V, Peters S, Vienne M, Moeckli R, Bourhis J. Apnea-like suppression of respiratory motion: First evaluation in radiotherapy. Radiother Oncol. 2016;118(2):220-6.

91. Peters S, Zimmermann S. The French initiative paves the way: routine molecular profiling of advanced non-small-cell lung cancer fights inequalities in access to molecular targeted therapy and improves patient outcome. Transl Cancer Research. 2016; 5.2:124-126.

90. Peters S. Emerging Options After Progression During Crizotinib Therapy. J Clin Oncol. 2016;34(7):643-5.

89. Tabernero, J and ESMO Executive Board. Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no ‘sweetheart’ solution. Annals of Oncology. 2015 ; 26: 1529–1531.

88. Wang X, Gronchi F, Bensimon M, Mercier T, Decosterd LA, Wagnières G, Debefve E, Ris HB, Letovanec I, Peters S, Perentes JY. Treatment of pleural malignancies by photo-induction combined to systemic chemotherapy: Proof of concept on rodent lung tumors and feasibility study on porcine chest cavities. Lasers Surg Med. 2015;47(10):807-16.

87. Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27(2):281-6.

86. Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik LF, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651-8.

85. Rolfo C, Gil-Bazo I, Peters S. Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer. European Oncology & Haematology, 2015;11(2):94–9.




84. Favre-Bulle T, Baudat D, Darling K, Mamin R, Peters S, Cavassini M, Hugli O. Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study. Swiss Med Wkly. 2015;145:w14206.

83. Serena A, Castellani P, Fucina N, Griesser AC, Jeanmonod J, Peters S, Eicher M. The role of advanced nursing in lung cancer: A framework based development. Eur J Oncol Nurs. 2015;19(6):740-6.

82. Peters S, von Moos R, Thurlimann B. [Is prescription of a therapy costing 150,000 CHF reasonable?]. Rev Med Suisse. 2015;21;11(491):1967-72. German.

81. Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015;10(10):1396-403.

80. Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol. 2015;10(10):1451-7.

79. Pentheroudakis G, Cardoso F, Arnold D, Sessa C, Peters S, Horwich A, Pavlidis N, Stahel R, Cervantes A; ESMO Guidelines Committee. The ESMO guideline strategy: an identity statement and reflections on improvement. Ann Oncol. 2015;26 Suppl 5:v1-7.

78. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S; ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v40-55.

77. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v31-9

76. Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer. 2015;16(5):358-65.

75. Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S; SAKK Lung Cancer Project Group. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet. 2015;386(9998):1049-56. Erratum in: Lancet. 2015;386(9998):1040.

74. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S; Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26(8):1573-88.

73. Stahel RA, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I, Peters S. Searching for targets for the systemic therapy of mesothelioma. Ann Oncol. 2015;26(8):1649-60.




72. Zimmermann S, Peters S. Present standards and future perspectives in the treatment of metastatic

non-small cell lung cancer. Cancer Metastasis Rev. 2015;34(2):173-82.

71. Stahel RA, Bogaerts J, Ciardiello F, de Ruysscher D, Dubsky P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart M, Smit EF, Sotiriou C, Tejpar S, Van Cutsem E, Tabernero J. Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treat Rev. 2015;41(2):129-135.

70. Peters S, Adjei AA. Lung cancer: How much platinum-based chemotherapy is enough in NSCLC? Nat Rev Clin Oncol. 2015;12(1):8-10.

69. Merz L,Peters S, Zimmermann S, Cavassini M, Darling K. Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. J Int AIDS Soc. 2014; 17: 19622.

68. Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. 2014, Transl Lung Cancer Res 2014;3(2):84-88.

67. Peters S, Smit EF. Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer. Lancet Oncol. 2014;15(12):1289-90.

66. Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit EF, Dingemans AMC, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA; ETOP Lungscape Investigators. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol. 2014;9(11):1675-84.

65. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii27-39.

64. Mosimann V, Cavassini M, Hugli O, Mamin R, Achtari C, Peters S, Darling KEA. Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV-testing practices in a Swiss university hospital. HIV Med. 2014;15(10):631-4.

63. Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Res. 2014;24(5):496-500.

62. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel RA, Peters S, Felip E, Panel members. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681-90.

61. Blackhall FH*, Peters S*, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, Stahel RA. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol. 2014;32(25):2780-7.

60. Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer Treat Rev. 2014;40(8):917-26.


http://www.ncbi.nlm.nih.gov/pubmed/?term=Merz%20L%5Bauth%5D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Zimmermann%20S%5Bauth%5D

http://www.ncbi.nlm.nih.gov/pubmed/?term=Cavassini%20M%5Bauth%5D



59. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters

S, Piccart M, Popescu R, Van Cutsem E, Zielinski C, Stahel RA. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25(9):1673-8.

58. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel RA, Felip E, Peters S, Panel members. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014;25(8):1475-84.

57. Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, Stahel RA, Peters S, Felip E, Panel members. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. AnnOncol. 2014;25(8):1462-74.

56. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-50.

55. Dafni U, Karlis D, Smit EF, Peters S. Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out. Lung Cancer. 2014 Jun;84(3):314-5.

54. Bouchaab H, Peters S, Ozsahin M, Peguret N, Gonzales M, Lovis A. Postoperative radiation therapy in lung carcinom. Rev Med Suisse. 2014;10(431):1110-3.

53. Perentes JY, Wang Y, Wang X, Abdelnour E, Gonzalez M, Decosterd L, Wagnieres G, van den Bergh H, Peters S, Ris HB, Krueger T. Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model. Transl Oncol. 2014: S1936-5233(14)00045-X.

52. Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev. 2014;40(6):716-22.

51. Voide C, Zimmermann S, Adjei AA, Betticher DC, Meuli R, Prod'hom G, Giulieri S, Peters S. Cerebral nocardiosis mimicking multiple brain metastases in a patient with locally advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(3):e24-6.

50. Peters S, Raymond E, Coukos G. L’oncologie «de précision»: un incontournable changement pour notre discipline, une révolution pour nos patients. Bulletin Suisse du Cancer. 2014;1:14-16.

49. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 2014;40(2):300-6.

48. Stahel RA, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer. 2013;82(3):375-82.

47. Stravodimou A, Peters, S. Personalized Treatment of Advanced Non-small Cell Lung Cancer: EGFR Tyrosine Kinase Inhibitors as a Standard of Care. J Oncopathol. 2013; 1(4):63-71.




46. Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer. 2013 ;82(2):365-7.

45. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res. 2013;19(20):5749-57.

44. Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E; ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi99-105.

43. Zimmermann S, Peters S. Practical tips and tricks with recently approved molecular targeted agents in non-small-cell lung cancer. EJC suppl. 2013 Sep; 11(2): 307–309.

42. Peters S, Taron M, Bubendorf L, Blackhall FH, Stahel RA. Treatment and detection of ALK-rearranged NSCLC. Lung Cancer. 2013;81(2):145-54.

41. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol. 2013;31(20):e341-4.

40. Gonzalez M, Litzistorf Y, Krueger T, Popeskou SG, Matzinger O, Ris HB, Gronchi F, Lovis A, Peters S. Impact of induction therapy on airway complications after sleeve lobectomy for lung cancer. Ann Thorac Surg. 2013;96(1):247-52.

39. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S; ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi89-98.

38. Mazières J*, Peters S*, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003.

37. Lee JA, Bubendorf L, Stahel RA, Peters S. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Expert Rev Anticancer Ther. 2013;13(5):625-36.

36. Demierre N, Zoete V, Michielin O, Stauffer E, Zimmermann DR, Betticher DC, Peters S. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? Lung Cancer. 2013;80(1):81-4.

35. Peters S, Meylan E. Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. Curr Opin Oncol. 2013;25(2):137-44.

34. Gautschi O, Dingemans AMC, Crowe S, Peters S, Roder H, Grigorieva J, Roder J, Zappa F, Pless M, Brutsche M, Baty F, Bubendorf L, Hsu Schmitz SF, Na KJ, Carbone D, Stahel RA, Smit EF. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer. 2013;79(1):59-64.




33. Perentes J, Bopp S, Krueger T, Gonzalez M, Jayet PY, Lovis A, Matzinger O, Ruffieux C, Ris HB,

Letovanec I, Peters S. Impact of lung function changes after induction radiochemotherapy on resected T4 non-small cell lung cancer outcome. Ann Thorac Surg. 2012;94(6):1815-22.

32. Vallières E, Peters S, Van Houtte P, Dalal P, Lim E. Therapeutic advances in non-small cell lung cancer. Thorax. 2012;67(12):1097-101.

31. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, and Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii56-64.

30. Zimmermann S, Peters S. Going beyond EGFR. Ann Oncol. 2012;23(suppl 10):x197-203.

29. Krueger T, Perentes JY, Peters S, Ris HB, Gonzalez M. VATS lobectomy for early-stage primary lung cancer. Rev Med Suisse. 2012;8(346):1337-41.

28. Gonzalez M, Peters S, Wang Y, Ris HB, Krueger T. Management pulmonary metastases: when operate?. Rev Med Suisse. 2012 Jun 20;8(346):1326-31.

27. Peters S, Meylan E. RANKing lung cancer bone metastasis, editorial. Lung Cancer Management. 2012;1(2):87-90

26. Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30(17):e156-9.

25. Stahel RA, Peters S. Lung cancer: New evidence - new realities - new challenges, editorial. Bulletin Suisse du cancer. 2012;2:91-92.

24. Serena A, Griesser Anne-Claude, Débarge P, Fucina N, Peters S, Eicher M. Unmet supportive care needs of lung cancer patients during the chemotherapy phase: A descriptive study. Bulletin Suisse du cancer 2012;2:118-122.

23. Darling KEA, Hugli O, Mamin R, Cellerai C, Martenet S, Berney A, Peters S, Du Pasquier RA, Bodenmann P, Cavassini M. HIV testing practices by clinical service before and after revised testing guidelines in a Swiss University Hospital. PLoS One. 2012;7(6):e39299.

22. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9(6):314-26.

21. Wang Y, Gonzalez M, Cheng C, Haouala A, Krueger T, Peters S, Decosterd LA, van den Bergh H, Perentes JY, Ris HB, Letovanec I, Debefve E. Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. Lasers Surg Med. 2012;44(4):318-24.

20. Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with




gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer. 2012;48(3):377-84.

19. Cheng C, Wang Y, Haouala A, Debefve E, Andrejevic Blant S, Krueger T, Gonzalez M, Ballini JP, Peters S, Decosterd L, van den Bergh H, Ris HB, Perentes JY. Photodynamic therapy enhances liposomal doxorubicin distribution in tumors during isolated perfusion of rodent lungs. Eur Surg Res. 2011;47(4):196-204.

18. Gonzalez M, Krueger T, Perentes JY, Matzinger O, Peters S, Ris HB. Extrapleural pneumonectomy with venous confluence resection for stage IVA thymic tumors. Ann Thorac Surg. 2011;91(3):941-3.

17. Stupp R, Betticher D, Ris HB, Peters S, Pless M. Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach. J Clin Oncol. 2011;29(5):e118-9.

16. Cheng C, Debefve E, Haouala A, Andrejevic-Blant S, Krueger T, Ballini JP, Peters S, Decosterd L, van den Bergh H, Wagnieres G, Perentes JY, Ris HB. Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs. Lasers Surg Med. 2010;42(5):391-9.

15. Wagner AD, Zaman K, Peters S, Montemurro M, Leyvraz S. Anti-angiogenic therapies for metastatic colorectal, breast and lung cancer: benefits and risks. Rev Med Suisse. 2010;6(250):1070-3.

14. Berthod G, Bouzourene H, Pachinger C, Peters S. Solitary choriocarcinoma in the lung. J Thorac Oncol. 2010;5(4):574-5.

13. Rüegg C, Peters S. Thalidomide in small cell lung cancer: wrong drug or wrong disease? J Natl Cancer Inst. 2009;101(15):1034-5.

12. Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, Roth AD, Stahel RA, Majno SB, Peters S, Jost L, Furrer M, Thierstein S, Schmid RA, Hsu Schmitz SF, Mirimanoff RO, Ris HB, Pless M. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009;10(8):785-93.

11. Cheng C, Haouala A, Krueger T, Mithieux F, Perentes JY, Peters S, Decosterd LA, Ris HB. Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. Interact Cardiovasc Thorac Surg. 2009;8(6):635-8.

10. Peters S, Betticher DC. The role of EGFR in non-small cell lung carcinoma. Rev Med Suisse. 2009;5(204):1096-8, 1100-1.

9. Voelter V, Schalenbourg A, Pampallona S, Peters S, Halkic N, Denys A, Goitein G, Zografos L, Leyvraz S. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res. 2008;18(3):220-4.

8. Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G. Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst. 2008;100(8):533-41.




7. Yan H, Cheng C, Haouala A, Krueger T, Ballini JP, Peters S, Decosterd LA, Letovanec I, Ris HB, Andrejevic-Blant S. Distribution of free and liposomal doxorubicin after isolated lung perfusion in a sarcoma model. Ann Thorac Surg. 2008;85(4):1225-32.

6. Peters S, Lüthi F, Leyvraz S. Urgences oncologiques: chapitres choisis. Forum Med Suisse. 2006;6:718-725.

5. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. 2006;17(4):578-83.

4. Bleiber G, Peters S, Martinez R, Cmarko D, Meylan P, Telenti A. The central region of human immunodeficiency virus type 1 p6 protein (Gag residues S14-I31) is dispensable for the virus in vitro. J Gen Virol. 2004;85(Pt 4):921-7.

3. Telenti A, Martinez R, Munoz M, Bleiber G, Greub G, Sanglard D, Peters S. Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J Virol. 2002;76(15):7868-73.

2. Peters S, Muñoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P, Telenti A. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J Virol. 2001;75(20):9644-53.

1. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses. 2000;16(13):1209-13.

*Equal contribution Book Chapters

8. Peters S, Side Effects of Medical Cancer Therapy, 2nd Edition. Springer Verlag

7. Peters S, Mirimanoff RO. Tumeurs rares, Thérapeutique oncologie. Springer Verlag, 2011

6. Peters S. Tumeurs médiastinales, Cancers thoraciques. Springer Verlag, 2011

5. Peters S, Stahel R.A., Side effects of medical cancer therapy – lung cancer. Springer Verlag UK, 2012

4. Soltermann A, Peters S, Tischler V. Lung Cancer therapy Annual, chapter Histo- and molecular pathology of lung cancer. Informa book, 2012

3. Joerger M, Peters S, Stahel R.A. Clinical Evidence of Bevacizumab in Non Small-Cell Lung Cancer (NSCLC). "Bevacizumab in Lung Cancer: its impact & exceptional cases". Athens Medical School Publications, 2013

2. Ris HB, Matzinger O, Lovis A, Peters S. Surgery in the Context of Multimodal Treatment of Non-Small Cell Lung Cancer. Incisions, nœuds et réseaux, Les 100 ans Société Suisse de Chirurgie. Swiss Surgery Society Edition, 2013




1. Zimmermann S, Peters S. Systemic treatment of lung cancer. Oxford Textbook of Oncology, 3rd

edition, 2014

Book Editions

7. Progress in Tumor Research Vol. 41, 2014. Tumors in Adolescents and Young Adults. Series Editors: Peters S, Stahel. Karger AG, Medical and Scientific Publishers, Switzerland, 2016

6. Progress in Tumor Research Vol. 41, 2014. Immuno-Oncology. Series Editors: Peters S, Stahel.

Karger AG, Medical and Scientific Publishers, Switzerland, 2015

5. Co-editor ESMO book - Thoracic Tumours: Essentials for Clinicians, 2014

4. Progress in Tumor Research Vol. 41, 2014. Successes and Limitations of Targeted Cancer Therapy. Editors: Peters S, Stahel, RA. S. Karger AG, Medical and Scientific Publishers, Switzerland

3. Co-editor "Essentials for oncologists on Thoracic cancers", ESMO publications, 2013 and 2017

2. Series editors Stahel RA, Peters S. "Progress in Tumor Research", S. Karger AG, Medical and Scientific Publishers, Switzerland

1. Co-editor of "Perspectives in Thoracic Oncology", UNI-MED (Germany), 2012


Curriculum Vitae Solange PETERS, MD-PhD · Permanent advisory board member for Framingham on lung...

Documents

Transcript of Curriculum Vitae Solange PETERS, MD-PhD · Permanent advisory board member for Framingham on lung...